Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Polypharmacy in psychiatry practice . Volume 1 Multiple medication use strategies / / Michael S. Ritsner, editor
| Polypharmacy in psychiatry practice . Volume 1 Multiple medication use strategies / / Michael S. Ritsner, editor |
| Edizione | [1st ed. 2013.] |
| Pubbl/distr/stampa | Dordrecht, : Springer, 2013 |
| Descrizione fisica | 1 online resource (295 p.) |
| Disciplina |
615.7/88
615.788 616.8918 |
| Altri autori (Persone) | RitsnerMichael S |
| Soggetto topico |
Polypharmacy
Psychopharmacology |
| ISBN |
1-299-40842-7
94-007-5805-7 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Polypharmacy in Psychiatry Practice Volume I; About the Editor; Preface; Contents; Contributors; Part I: Polypharmacy Treatment Strategies; Chapter 1 : Multiple Psychiatric Medications Use in Psychiatry: How Rational Can It Be?; 1.1 Introduction; 1.2 Rationale for MMU in HIV; 1.3 Rationale for MMU in Cancer; 1.4 Rationale for MMU in Parkinson's Disease; 1.5 The Principles and the Rationale for MPMU; 1.5.1 Pharmacokinetic Drug Interactions; 1.5.2 Pharmacodynamic Drug Interactions; 1.5.3 Interactions Involving both Pharmacokinetic and Pharmacodynamic Mechanisms
1.6 Conclusions and Future DirectionsReferences; Chapter 2: Receptor Binding Targets for Antipsychotic Efficacy; 2.1 Introduction; 2.2 Methods; 2.2.1 Data Analysis; 2.3 Results; 2.4 Discussion; 2.4.1 D3 Dopamine Receptor Provides a Molecular Binding Target for Antipsychotic Efficacy; 2.4.2 Serotonin Receptor Contributions to Antipsychotic Efficacy; 2.5 Limitations; 2.6 Conclusions and Future Directions; References; Chapter 3: Drug Interactions and Polypharmacy; 3.1 Introduction; 3.2 Pharmacodynamic Interactions; 3.2.1 Pharmacodynamic Drug Interaction Classification 3.2.2 Time Course of Pharmacodynamic Interactions3.2.3 Serious Pharmacodynamic Interactions; 3.2.3.1 Hypertension and Hypertensive Crisis; 3.2.3.2 Serotonin Syndrome; 3.2.3.3 Bleeding; 3.2.3.4 Psychosis and Extrapyramidal Side Effects; 3.2.3.5 CNS Depression; 3.2.3.6 Anticholinergic Effects; 3.2.3.7 Arrhythmias/QTc Prolongation; 3.3 Pharmacokinetic Drug Interactions; 3.4 Clinical Effects of Drug Interactions; 3.4.1 Risk Factors; 3.5 Drug Interaction Software; 3.6 Prevention and Management of Drug Interactions; 3.7 Resources for Assessing Drug Interactions; 3.8 Conclusions Appendix. Commonly Encountered Psychotropic Interactions [ 9, 47, 59, 74 ]References; Chapter 4: Preclinical and Clinical Investigation of Antipsychotic Polypharmacy: What Is the Evidence?; 4.1 Introduction; 4.2 What Is the Preclinical Evidence for Antipsychotic Polypharmacy?; 4.3 Antipsychotic Polypharmacy in Clinical Practice; 4.3.1 Prevalence of Antipsychotic Polypharmacy; 4.3.2 Explaining the Differences in Prevalence of Antipsychotic Polypharmacy Among Studies; 4.3.3 Does the Prevalence of Polypharmacy Depend on the Baseline Antipsychotic Agent? 4.3.4 Prevalence of Polypharmacy: Change Over Time4.3.5 Predictors of Polypharmacy; 4.3.5.1 Patient Factors; 4.3.5.2 Setting and Therapists Factors; 4.3.6 Other Factors Associated with Antipsychotic Polypharmacy; 4.3.6.1 Mortality; 4.3.6.2 Increased Total Antipsychotic Dose; 4.3.6.3 Cost; 4.3.6.4 Cognitive Impairment; 4.4 Efficacy of Polypharmacy; 4.4.1 Meta-analyses; 4.4.2 Reviews; 4.4.3 Discontinuation Studies; 4.5 Management of Antipsychotic Polypharmacy; 4.6 Discussing the Evidence; 4.7 Conclusions and Future Directions; References Chapter 5: Should High Dose or Very Long-Term Antipsychotic Monotherapy Be Considered Before Antipsychotic Polypharmacy? |
| Record Nr. | UNINA-9910437844903321 |
| Dordrecht, : Springer, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Polypharmacy in psychiatry practice . Volume 2 Use of polypharmacy in the "Real World" / / edited by Michael S. Ritsner
| Polypharmacy in psychiatry practice . Volume 2 Use of polypharmacy in the "Real World" / / edited by Michael S. Ritsner |
| Edizione | [1st ed. 2013.] |
| Pubbl/distr/stampa | Dordrecht, : Springer, 2013 |
| Descrizione fisica | 1 online resource (326 p.) |
| Disciplina |
615.7/88
616.8918 |
| Altri autori (Persone) | RitsnerMichael S |
| Soggetto topico |
Polypharmacy
Psychopharmacology |
| ISBN |
1-299-40841-9
94-007-5799-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Antipsychotic polypharmacy for schizophrenia: 'Secret sauce' or 'wild abandon'? -- Antipsychotic polypharmacy in USA -- Antipsychotic polypharmacy in Czech Republic and in Ukraine -- Antipsychotic polypharmacy in residential facilities in Italy: the gap between recommendations and real world practice -- Antipsychotic polypharmacy and associated phenomena in patients with schizophrenia: Rational or irrational? -- Antipsychotic polypharmacy in schizophrenia. How to counteract this common practice? -- Clozapine combinations in treatment-resistant schizophrenia patients -- Metabolic syndrome and antipsychotic polypharmacy -- Evidence based combination therapy for bipolar disorder -- Antidepressant combination strategies for major depressive disorder -- Herbal remedies and nutraceuticals as augmentation or adjunct for mood and anxiety disorders: evidence for benefit and risk -- Obsessive-compulsive syndromes in schizophrenia: A case for polypharmacy? -- Polypharmacy and potentially inappropriate medication use among elders with dementia -- The role of polypharmacy in bipolar disorder treatment guidelines. |
| Record Nr. | UNINA-9910437842403321 |
| Dordrecht, : Springer, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||